升荣口服液联合XELOX化疗治疗原发性肝癌的疗效观察  

Therapeutic effect of Shengrong oral liquid combined with XELOX chemotherapy in the treatment of primary liver cancer

作　　者：马军[1] 罗居东 景文江[1] 张淑莲[1] 王娟毅[1] 范志刚[1] MA Jun;LUO Ju-dong;JING Wen-jiang(Shanxi Hanzhong(723000)China)

机构地区：[1]西安交通大学医学院附属汉中3201医院肿瘤科,陕西汉中723000 [2]南京医科大学附属常州第二人民医院肿瘤中心

出　　处：《中西医结合肝病杂志》2019年第3期228-229,235,共3页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：陕西省科技厅科技研究发展计划项目(No.2005K16-G4);江苏省科技厅重点研发项目(No.BE2018643)

摘　　要：目的:观察中药复方升荣口服液联合XELOX化疗治疗原发性肝癌的疗效与不良反应。方法:按照课题设计共纳入77例患者,按照随机数字表法分为观察组(升荣口服液+化疗)和对照组(单纯化疗),观测指标包括:肿瘤评定、免疫功能、血常规肝功能及不良反应。结果:观察组总有效率为77.50%(31/40),对照组总有效率为56.76%(21/37),差异具有统计学意义(P<0.05),观察组患者ECOG评分、外周血细胞计数、甲胎蛋白指数及肝功能等方面均优于对照组(P<0.05),疼痛、纳差、腹泻、恶心、触电感及黏膜炎等毒性较对照组改善显著(P<0.05)。结论:升荣口服液联合XELOX化疗治疗原发性肝癌能提高患者生活质量、改善肝功能、降低不良反应,具有临床推广价值。Objective:To observe the curative effect and adverse reactions of Shengrong oral liquid combined with XELOX chemotherapy for primary liver cancer.Methods:According to the study design, a total of 77 patients were included and divided into the combined treatment group(shengrong oral solution + chemotherapy) and the control group(chemotherapy alone) according to the random number table. Results:Total effective rate(CR+PR+SD) was 77.50%(31/40) in the observation group, the total effective rate of the control group was 56.76%(21/37), with significant difference(P<0.05), ECOG score, peripheral blood trisomy cells, alpha fetoprotein index and liver function in the combined treatment group were superior to the control group(P<0.05), and toxicity such as pain, tolerance, diarrhea, nausea, electric shock and mucositis were significantly improved compared with the control group(P<0.05).Conclusion:Shenrong oral solution combined with XELOX chemotherapy to treat primary liver cancer can provide quality of life, improve liver function and reduce adverse reactions, and has clinical promotion value.

关 键 词：升荣口服液 肝癌 奥沙利铂 卡培他滨 

分 类 号：R735.7[医药卫生—肿瘤]